Decoding 9 Analyst Evaluations For Clorox
Portfolio Pulse from Benzinga Insights
Recent analyst evaluations of Clorox (NYSE:CLX) show a mixed sentiment, with the majority being indifferent. Over the past three months, 9 analysts have provided ratings, with 7 being indifferent, 1 somewhat bearish, and 1 bearish. The average 12-month price target for Clorox is now $153.89, down from $155.50, indicating a slight negative adjustment in expectations. Analysts from Citigroup, Barclays, Morgan Stanley, Jefferies, Goldman Sachs, DA Davidson, UBS, and JP Morgan have adjusted their ratings and price targets, reflecting a nuanced view of Clorox's market position, financial performance, and future prospects.
April 16, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Analysts show mixed sentiments towards Clorox, with a majority indifferent but adjustments in price targets suggest a cautious outlook. The average price target has been slightly reduced, indicating potential pressure on the stock price in the short term.
The reduction in the average price target and the predominance of indifferent ratings among analysts suggest a cautious or negative outlook for Clorox in the short term. This could lead to potential pressure on the stock price as investors adjust their expectations based on these analyst evaluations. The detailed adjustments by analysts from notable firms further underscore the nuanced view of Clorox's current financial health and market position, which could influence investor sentiment and stock performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100